Wednesday, August 20, 2008

BioImagene Gets $26M In Series D Funding

Cupertino-based BioImagene, a developer of digital pathology products used in cancer diagnostics and for preclinical research, said Tuesday that the firm has raised $26M in a Series D funding round. The round was led by Burrill & Company. Other investors in the round included Ascension Health Ventures, National Healthcare Services, Artiman Ventures and ICCP Ventures. BioImagene's products are used for digital pathology. More information »